Resultados de la búsqueda 1-10 of 13327 for Emicizumab

  1. Bispecific antibody therapy

    Other diseases. Emicizumab (Hemlibra) binds factor IXa and factor X proteins to help prevent bleeding in people with hemophilia A. Faricimab (Vabysmo) blocks ...

  2. Bispecific antibody therapy - Mayo Clinic

    Other diseases. Emicizumab (Hemlibra) binds factor IXa and factor X proteins to help prevent bleeding in people with hemophilia A. Faricimab (Vabysmo) blocks ...

  3. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

  4. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

  5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in ...

  6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in ...

  7. Hematología - Ensayos clínicos - Mayo Clinic

    This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in ...

  8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with ...

  9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as obinutuzumab, may ...

  10. Ensayos clínicos - Centro Pediátrico de Mayo Clinic

    Selumetinib is a drug that works by blocking some enzymes that low grade glioma tumor cells need for their growth. This results in killing tumor cells. Drugs ...